

A New Simplified System for the Evaluation of BNCT Pharmaceuticals

T. E. Byrne, L. F. Miller,¹ G. W. Kabalka,² and R. C. Martin³RECEIVED
JAN 28 1999
OSTIBiology Department
Roane State Community College
Harriman, TN 37748¹Nuclear Engineering Department, The University of Tennessee, Knoxville, TN 37996²Chemistry Department, The University of Tennessee, Knoxville, TN 37996³Chemical Technology Division, Oak Ridge National Laboratory,[†]
Oak Ridge, TN 37831-6385Presented at the
Eighth International Symposium on Neutron Capture Therapy for Cancer
La Jolla, California
September 13-18, 1998

"The submitted manuscript has been authored by a contractor of the U.S. Government under contract No. DE-AC05-96OR22464. Accordingly, the U.S. Government retains a nonexclusive, royalty-free license to publish or reproduce the published form of this contribution, or allow others to do so, for U.S. government purposes."

[†]Managed by Lockheed Martin Energy Research Corp., under contract DE-AC05-96OR22464 with the U.S. Department of Energy.

DISCLAIMER

This report was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor any agency thereof, nor any of their employees, make any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof.

DISCLAIMER

**Portions of this document may be illegible
in electronic image products. Images are
produced from the best available original
document.**

A New Simplified System for the Evaluation of BNCT Pharmaceuticals

T. E. Byrne¹, L. F. Miller², G. W. Kabalka³ and R. C. Martin⁴

¹ Roane State, Harriman, Tenn. ²University of Tennessee, Knoxville, Nuclear Engineering Department, ³University of Tennessee, Knoxville, Chemistry Department, ⁴Oak Ridge National Laboratory, Oak Ridge, Tennessee

A system for testing potential BNCT pharmaceuticals in cell cultures has been developed with the cooperation of Oak Ridge National Laboratory (ORNL), the University of Tennessee Chemistry Department and the University of Tennessee Nuclear Engineering Department. A BNCT test model has been established with the use of the human lung cancer cell line A 549. These cells were maintained in standard laboratory facilities and subjected to boronated chemicals. Following toxicity studies the human lung cancer cells were exposed to ²⁵²Cf neutron sources provided by the Radiochemical Engineering Development Center (REDC) at ORNL. The isotope ²⁵²Cf performs effectively for BNCT applications. The neutron spectrum is similar to that of a reactor fission source with an average energy of 2.1 MeV. A 50 mg source of ²⁵²Cf moderated by water provides a source on the order of 1×10^9 thermal neutrons/cm²/sec at a distance of 3 cm. The half-life of ²⁵²Cf is 2.65 years, and thus may provide a simple and reliable source of neutrons for BNCT in locations without suitable nuclear reactors. The REDC of ORNL stores and processes the U.S. stockpile of ²⁵²Cf.

The compounds examined were boron-containing nucleosides and boron-containing amino acids (Figure 1). Chemical analysis for the measurement of total cellular boron was conducted at ORNL using inductively

coupled plasma mass spectroscopy. Boron concentrations were measured against a calibration curve generated with a series of NIST standards. In nitric acid solutions containing boron, the detection limit was 0.4 ppb. In similar solutions containing cellular debris the boron detection limit was determined to be 1.0 ppb.

Calculations of cellular dosimetry in human lung cancer cells from sources of ^{252}Cf and intracellular ^{10}B concentrations have been made (Table 1). All experiments with thermal neutrons plus boronated pharmaceutical compounds displayed a greater cancer cell killing effect than control experiments without boronated compounds (Figure 2). Thus, a cooperative program for the future evaluation of BNCT pharmaceutical agents is now in place.

In conclusion, the following objectives of this research have been achieved:

1. The cellular toxicity of the proposed BNCT compounds has been determined. The least toxic agent of the A549 lung cancer cell is ACBC followed by LSK 1-38, CDU-4 and the most toxic agent is CN-V-264.
2. The cellular uptake of the BNCT compounds has been determined. The greatest cellular uptake of B/cell occurred with ACBC at a concentration of $24.6 \times 10^{-3} \text{ ng}$ followed by LSK 1-38 with a concentration of $8.6 \times 10^{-3} \text{ ng B}/\text{cell}$, CN-V-264 demonstrated an uptake concentration of $4.5 \times 10^{-3} \text{ ng B}/\text{cell}$ and CDU-4 displayed the lowest uptake concentration of $.9 \times 10^{-3} \text{ ng B}/\text{cell}$.

3. A 30 mg source of ^{252}Cf moderated by 2.5 cm of water and polyethylene produced a thermal neutron flux of approximately 2×10^8 neutrons/cm 2 /sec. The REDC source allowed for the development of cellular survival curves in A549 lung cancer cells.

4. A system for testing potential BNCT pharmaceuticals in cell cultures has been developed with the cooperation of ORNL, the UTK Chemistry Department and the UTK Nuclear Engineering Department.

Acknowledgements: We wish to thank the U. S. Department of Energy (DOE), Oak Ridge National Laboratory (ORNL) and Lockheed Martin Idaho Technology University Research Consortium (URC) for support of this research.

Figure 1 The boronated chemicals used in this experiment.




Table 1

Uptake of boronated compounds by A549 lung cancer cells and calculated number of thermal neutron interactions per cell at four minute exposure.

| Compound | Boron in cell (ng B/cell) | Atoms of ^{10}B (atoms $^{10}\text{B}/\text{cell}$) | Average Number of interactions per cell |
|----------|------------------------------|------------------------------------------------------------------|-----------------------------------------------|
| ACBC | 24.6×10^{-3} | 274×10^9 | 5.0 |
| LSK 1-38 | 8.6×10^{-3} | 96×10^9 | 1.7 |
| CN-V-264 | 4.5×10^{-3} | 50×10^9 | 0.9 |
| CDU-4 | $.9 \times 10^{-3}$ | 10×10^9 | .18 |

Figure 2 Bar graph of effective kill constants with various boron containing compounds versus controls.

